Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CARISSA Trial - Multicenter Randomized Phase II Trial Comparing Post-Operative Radiotherapy and Cisplatin Alone or in Combination With the EGFR Inhibitor ZD 1839 (Iressa) [gefitinib] in Upper Aerodigestive Tract Carcinomas

Next Previous
X
Search
Trial Profile

CARISSA Trial - Multicenter Randomized Phase II Trial Comparing Post-Operative Radiotherapy and Cisplatin Alone or in Combination With the EGFR Inhibitor ZD 1839 (Iressa) [gefitinib] in Upper Aerodigestive Tract Carcinomas

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gefitinib (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Acronyms CARISSA; GORTEC GETTEC CARISSA

    • Most Recent Events

    • 14 Nov 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 14 Nov 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 07 Jun 2010 Researchers in this trial are aiming to identify a subgroup of patients with head and neck cancer who are sensitive to gefitinib. According to an abstract presented at ASCO 2010, samples from 82 patients have been collected towards this end, to date.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top